Diseases /

Large B-Cell Lymphoma with IRF4 Rearrangement

Associated Genetic Biomarkers

Overview

NCI Definition: A germinal center-derived B-cell lymphoma that affects predominantly children and young adults. It is characterized by the presence of strong IRF4 expression and IRF4 translocation, BCL2 expression, and the absence of t(14;18)(q32;q21). It affects the Waldeyer's ring, head and neck lymph nodes, and the intestine. Morphologically it is characterized by the presence of diffuse and grade 3 follicular areas. [1]

Clinical Trials

There
is 1 clinical trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is
open and 0
are
completed or closed.
Of the
trial that contains
large B-cell lymphoma with IRF4 rearrangement as an inclusion criterion, 1 is phase 2 (1 open).

AFF1, ALK, and BCL2
are the most frequent gene inclusion
criteria for
large B-cell lymphoma with IRF4 rearrangement clinical trials [3].

Trials Investigating Large B-Cell Lymphoma With IRF4 Rearrangement by Gene and Recruiting Status

Nivolumab and varlilumab
are the most common
interventions in
large B-cell lymphoma with IRF4 rearrangement clinical trials.

Drugs Being Investigated in Large B-Cell Lymphoma With IRF4 Rearrangement Trials by Recruiting Status

Significant Genes in Large B-Cell Lymphoma with IRF4 Rearrangement

AFF1
+

AFF1 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
AFF1 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK
+

ALK is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
ALK status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

BCL2
+

BCL2 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
BCL2 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

BCL6
+

BCL6 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
BCL6 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL
+

ELL is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
ELL status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

IRF4
+

IRF4 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
IRF4 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A
+

KMT2A is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
KMT2A status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1
+

MLLT1 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
MLLT1 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10
+

MLLT10 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
MLLT10 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3
+

MLLT3 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
MLLT3 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4
+

MLLT4 is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
MLLT4 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC
+

MYC is an inclusion eligibility criterion in 1 clinical
trial
for large B-cell lymphoma with IRF4 rearrangement, of which 1
is open and 0
are closed.
Of the
trial that contains
MYC status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

LBCL with IRF4 Rearrangement

Parent(s)

Mature B-Cell Non-Hodgkin Lymphoma

OncoTree Name

Large B-Cell Lymphoma with IRF4 Rearrangement

OncoTree Code

LBLIRF4

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.